Compare · ELMD vs TMDX
ELMD vs TMDX
Side-by-side comparison of Electromed Inc. (ELMD) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELMD and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.17B, about 16.0x ELMD ($198.8M).
- TMDX has been more active in the news (8 items in the past 4 weeks vs 4 for ELMD).
- TMDX has more recent analyst coverage (20 ratings vs 3 for ELMD).
- Company
- Electromed Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $198.8M
- $3.17B
- 1M return
- -
- +29.47%
- 1Y return
- -
- -19.14%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2011
- 2019
- News (4w)
- 4
- 8
- Recent ratings
- 3
- 20
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest ELMD
- SEC Form 10-Q filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter
- Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026
- SEC Form DEF 14A filed by Electromed Inc.
- SEC Form DEFA14A filed by Electromed Inc.
- Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event
- SEC Form 4 filed by Electromed Inc.
- SEC Form 4 filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest TMDX
- Director Tobin James R sold $385,464 worth of shares (4,059 units at $94.97), decreasing direct ownership by 58% to 2,922 units (SEC Form 4)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Third Quarter 2026 Financial Results
- Officer Araujo Fernando N. was granted 22,969 shares (SEC Form 4)
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at Upcoming Investor Conferences
- TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Barclays initiated coverage on TransMedics Group with a new price target